Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor
Abstract Serologic biomarker to predict clinical outcome is needed for immune checkpoint inhibitors (ICIs). We evaluated soluble intercellular adhesion molecules‐1 (sICAM‐1) as a predictor of response to ICIs treatment. Ninety‐five patients with cancer treated with ICI were studied. The serum sICAM‐...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13540 |
| _version_ | 1797742126213103616 |
|---|---|
| author | Dongmei Ji Shiyu Jiang Qunling Zhang Y. Ken Wang Jian Zhang Weina Shen Wenhua Li Rujiao Liu Jessica Wang Cory Mavis Juan J. Gu Xichun Hu |
| author_facet | Dongmei Ji Shiyu Jiang Qunling Zhang Y. Ken Wang Jian Zhang Weina Shen Wenhua Li Rujiao Liu Jessica Wang Cory Mavis Juan J. Gu Xichun Hu |
| author_sort | Dongmei Ji |
| collection | DOAJ |
| description | Abstract Serologic biomarker to predict clinical outcome is needed for immune checkpoint inhibitors (ICIs). We evaluated soluble intercellular adhesion molecules‐1 (sICAM‐1) as a predictor of response to ICIs treatment. Ninety‐five patients with cancer treated with ICI were studied. The serum sICAM‐1 levels of baseline, post two cycle therapy and end of therapy (EOT) were measured by enzyme‐linked immunoassay. We randomly assigned the patients into the primary cohort (n = 47) and validation cohort (n = 48). Serum sICAM‐1 post two cycle (277.7 ± 181.6 ng/mL) and EOT (403.9 ± 218.9 ng/mL) were significantly elevated compared to baseline (244.8 ± 153.8 ng/mL, p = 0.008 and p = 0.004, respectively). Early changes of sICAM‐1 (ΔsICAM‐1), deemed as sICAM‐1 after two cycles minus baseline, were assessed. Following ICI treatments, responders had significantly lower ΔsICAM‐1 compared with nonresponders in the primary cohort (p = 0.040) and the validation cohort (p = 0.026). High ΔsICAM‐1 was strongly associated with inferior progression‐free survival (PFS; (primary cohort: p = 0.001 and validation cohort: p = 0.002) and overall survival (OS; (primary cohort: p < 0.001 and validation cohort: p = 0.007). The ΔsICAM‐1 remained independently associated with worse PFS and OS in the primary cohort and the validation cohort. Subgroup analysis indicated patients whose sICAM‐1 significantly elevated had shorter PFS and OS in both anti‐PD‐1 and anti‐PD‐L1 treatment groups. Early change of serum sICAM‐1 could be used to monitor and predict clinical benefit of ICI therapy in patients with solid cancer. |
| first_indexed | 2024-03-12T14:36:29Z |
| format | Article |
| id | doaj.art-b3bf6dc625e243009db43c8ca3711a57 |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-03-12T14:36:29Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-b3bf6dc625e243009db43c8ca3711a572023-08-17T06:29:48ZengWileyClinical and Translational Science1752-80541752-80622023-08-011681396140710.1111/cts.13540Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitorDongmei Ji0Shiyu Jiang1Qunling Zhang2Y. Ken Wang3Jian Zhang4Weina Shen5Wenhua Li6Rujiao Liu7Jessica Wang8Cory Mavis9Juan J. Gu10Xichun Hu11Department of Head and Neck Tumors and Neuroendocrine Tumors Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Oncology, Shanghai Medical College Fudan University Shanghai ChinaDepartment of Oncology, Shanghai Medical College Fudan University Shanghai ChinaDivision of Management and Education University of Pittsburgh Bradford Campus Bradford Pennsylvania USADepartment of Oncology, Shanghai Medical College Fudan University Shanghai ChinaDepartment of Oncology, Shanghai Medical College Fudan University Shanghai ChinaDepartment of Oncology, Shanghai Medical College Fudan University Shanghai ChinaDepartment of Oncology, Shanghai Medical College Fudan University Shanghai ChinaDepartment of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USADepartment of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USADepartment of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USADepartment of Oncology, Shanghai Medical College Fudan University Shanghai ChinaAbstract Serologic biomarker to predict clinical outcome is needed for immune checkpoint inhibitors (ICIs). We evaluated soluble intercellular adhesion molecules‐1 (sICAM‐1) as a predictor of response to ICIs treatment. Ninety‐five patients with cancer treated with ICI were studied. The serum sICAM‐1 levels of baseline, post two cycle therapy and end of therapy (EOT) were measured by enzyme‐linked immunoassay. We randomly assigned the patients into the primary cohort (n = 47) and validation cohort (n = 48). Serum sICAM‐1 post two cycle (277.7 ± 181.6 ng/mL) and EOT (403.9 ± 218.9 ng/mL) were significantly elevated compared to baseline (244.8 ± 153.8 ng/mL, p = 0.008 and p = 0.004, respectively). Early changes of sICAM‐1 (ΔsICAM‐1), deemed as sICAM‐1 after two cycles minus baseline, were assessed. Following ICI treatments, responders had significantly lower ΔsICAM‐1 compared with nonresponders in the primary cohort (p = 0.040) and the validation cohort (p = 0.026). High ΔsICAM‐1 was strongly associated with inferior progression‐free survival (PFS; (primary cohort: p = 0.001 and validation cohort: p = 0.002) and overall survival (OS; (primary cohort: p < 0.001 and validation cohort: p = 0.007). The ΔsICAM‐1 remained independently associated with worse PFS and OS in the primary cohort and the validation cohort. Subgroup analysis indicated patients whose sICAM‐1 significantly elevated had shorter PFS and OS in both anti‐PD‐1 and anti‐PD‐L1 treatment groups. Early change of serum sICAM‐1 could be used to monitor and predict clinical benefit of ICI therapy in patients with solid cancer.https://doi.org/10.1111/cts.13540 |
| spellingShingle | Dongmei Ji Shiyu Jiang Qunling Zhang Y. Ken Wang Jian Zhang Weina Shen Wenhua Li Rujiao Liu Jessica Wang Cory Mavis Juan J. Gu Xichun Hu Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor Clinical and Translational Science |
| title | Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor |
| title_full | Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor |
| title_fullStr | Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor |
| title_full_unstemmed | Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor |
| title_short | Early changes in soluble intracellular adhesion molecule‐1 as prognostic biomarkers to immune checkpoint inhibitor |
| title_sort | early changes in soluble intracellular adhesion molecule 1 as prognostic biomarkers to immune checkpoint inhibitor |
| url | https://doi.org/10.1111/cts.13540 |
| work_keys_str_mv | AT dongmeiji earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT shiyujiang earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT qunlingzhang earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT ykenwang earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT jianzhang earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT weinashen earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT wenhuali earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT rujiaoliu earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT jessicawang earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT corymavis earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT juanjgu earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor AT xichunhu earlychangesinsolubleintracellularadhesionmolecule1asprognosticbiomarkerstoimmunecheckpointinhibitor |